Answers are grounded in this paper and cite their sources.
BACKGROUND:The cardiac biomarkers N-terminal pro-brain natriuretic peptide (NT-proBNP) and troponin frequently are raised in patients with acute COVID-19.As a secondary analysis of the Right Ventricular Dysfunction in Ventilated Patients With COVID-19 study, we sought to determine the association between raised cardiac biomarkers and 1-year mortality in patients with COVID-19 receiving invasive mechanical ventilation (IMV).As an exploratory investigation, we combined point-of-care echocardiography and cardiac biomarker analyses to determine whether the biomarker signal represented a global or regional cardiac injury.STUDY QUESTION: Are abnormal cardiac biomarker levels associated with 1-year mortality in patients with COVID-19 requiring IMV? STUDY DESIGN AND METHODS: In this prospective cardiac biomarker and echocardiography study in patients with COVID-19 across 10 ICUs in the west of Scotland, patients underwent contemporaneous cardiac biomarker testing with point-of-care echocardiography between days 2 and 14 after intubation.Survival analyses was performed using univariable log-rank and multivariable Cox regression. RESULTS:One hundred twenty-one patients were recruited between September 2, 2020, and March 22, 2021.At 1 year, 57.6% of patients (68 of 118) had died.Patients with abnormal NT-proBNP levels and patients with abnormal troponin levels showed a 1-year mortality incidence of 71.4% (50 of 70) and 80.4% (45 of 56), respectively.Both abnormal NT-proBNP and abnormal troponin levels were associated with 1-year mortality (P < .001for both).Abnormal troponin level was associated with subjective right ventricular dysfunction (RVD; P .003),and no association with subjective left ventricular dysfunction was found (P .342).On multivariable analysis, abnormal NT-proBNP level, abnormal troponin level, and subjective RVD were associated independently with 1-year mortality (hazard ratios, 2.82 [95% CI, 1.19-6.67],2.84 [95% CI, 1.44-5.62],and 2.09 [95% CI, 1.07-4.07],respectively). INTERPRETATION:Abnormal NT-proBNP level, abnormal troponin level, and subjective RVD are associated independently with 1-year mortality in patients with COVID-19 receiving IMV.Cardiac biomarker testing and point-of-care echocardiography are available readily during ICU admission and may identify a group of patients who are at very high risk of poor outcomes.
No takes yet. Share an insight, caveat, or question.
McErlane et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: